Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment
- Author
- DONGIOVANNI, Paola1 ; ANSTEE, Quentin M2 ; VALENTI, Luca1
[1] Department of Pathophysiology and Transplantation, section Internal Medicine, Università degli Studi Milano, UO Medicina Interna 1B, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
[2] Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom - Issue title
- Update on Treatment Strategies in Patients with Non-Alcoholic Fatty Liver Disease
- Author (monograph)
- PETTA, Salvatore (Editor)1
[1] Sezione di Gastroenterologia Di.Bi.M.I.S. Università di Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy - Source
Current pharmaceutical design (Print). 2013, Vol 19, Num 29, pp 5219-5238, 20 p ; ref : 290 ref
- ISSN
- 1381-6128
- Scientific domain
- Pharmacology drugs
- Publisher
- Bentham, Sharjah
- Publication country
- United Arab Emirates
- Document type
- Article
- Language
- English
- Author keyword
- Non-alcoholic fatty liver disease genetic predisposition non-alcoholic steatohepatitis polymorphism
- Keyword (fr)
- Article synthèse Efficacité traitement Génotype Génétique Pathologie du foie Polymorphisme Prédisposition Stéatohépatite non alcoolique Variabilité génétique Pathologie de l'appareil digestif
- Keyword (en)
- Review Treatment efficiency Genotype Genetics Hepatic disease Polymorphism Predisposition Non alcoholic steatohepatitis Genetic variability Digestive diseases
- Keyword (es)
- Artículo síntesis Eficacia tratamiento Genotipo Genética Hígado patología Polimorfismo Predisposición Esteatohepatitis no alcohólica Variabilidad genética Aparato digestivo patología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B13 Gastroenterology. Liver. Pancreas. Abdomen / 002B13C Liver. Biliary tract. Portal circulation. Exocrine pancreas / 002B13C03 Other diseases. Semiology
- Discipline
- Gastroenterology. Liver. Pancreas. Abdomen General pharmacology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 27757606
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.2174/13816128113199990381 
https://dx.doi.org/10.2174/13816128113199990381
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.2174\/13816128113199990381\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:103:\"Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Current pharmaceutical design (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Curr. pharm. des. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:2:\"29\";s:8:\"\u0000*\u0000spage\";s:4:\"5219\";s:8:\"\u0000*\u0000epage\";s:4:\"5238\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"DONGIOVANNI\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Paola\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:17:\"ANSTEE, Quentin M\";i:1;s:13:\"VALENTI, Luca\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:81:\"Update on Treatment Strategies in Patients with Non-Alcoholic Fatty Liver Disease\";s:8:\"\u0000*\u0000title\";s:103:\"Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment\";s:8:\"\u0000*\u0000place\";s:7:\"Sharjah\";s:6:\"\u0000*\u0000pub\";s:7:\"Bentham\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"20\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.2174\/13816128113199990381\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:103:\"Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Current pharmaceutical design (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Curr. pharm. des. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:2:\"29\";s:8:\"\u0000*\u0000spage\";s:4:\"5219\";s:8:\"\u0000*\u0000epage\";s:4:\"5238\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"DONGIOVANNI\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Paola\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:17:\"ANSTEE, Quentin M\";i:1;s:13:\"VALENTI, Luca\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:81:\"Update on Treatment Strategies in Patients with Non-Alcoholic Fatty Liver Disease\";s:8:\"\u0000*\u0000title\";s:103:\"Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment\";s:8:\"\u0000*\u0000place\";s:7:\"Sharjah\";s:6:\"\u0000*\u0000pub\";s:7:\"Bentham\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"20\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:28:\"10.2174\/13816128113199990381\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.2174\/13816128113199990381\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:103:\"Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Current pharmaceutical design (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Curr. pharm. des. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:2:\"29\";s:8:\"\u0000*\u0000spage\";s:4:\"5219\";s:8:\"\u0000*\u0000epage\";s:4:\"5238\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"DONGIOVANNI\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Paola\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:17:\"ANSTEE, Quentin M\";i:1;s:13:\"VALENTI, Luca\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:81:\"Update on Treatment Strategies in Patients with Non-Alcoholic Fatty Liver Disease\";s:8:\"\u0000*\u0000title\";s:103:\"Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment\";s:8:\"\u0000*\u0000place\";s:7:\"Sharjah\";s:6:\"\u0000*\u0000pub\";s:7:\"Bentham\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"20\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.2174\/13816128113199990381\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:103:\"Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Current pharmaceutical design (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Curr. pharm. des. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:2:\"29\";s:8:\"\u0000*\u0000spage\";s:4:\"5219\";s:8:\"\u0000*\u0000epage\";s:4:\"5238\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"DONGIOVANNI\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Paola\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:17:\"ANSTEE, Quentin M\";i:1;s:13:\"VALENTI, Luca\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:81:\"Update on Treatment Strategies in Patients with Non-Alcoholic Fatty Liver Disease\";s:8:\"\u0000*\u0000title\";s:103:\"Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment\";s:8:\"\u0000*\u0000place\";s:7:\"Sharjah\";s:6:\"\u0000*\u0000pub\";s:7:\"Bentham\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"20\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.2174\/13816128113199990381\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:103:\"Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Current pharmaceutical design (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Curr. pharm. des. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:2:\"29\";s:8:\"\u0000*\u0000spage\";s:4:\"5219\";s:8:\"\u0000*\u0000epage\";s:4:\"5238\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"DONGIOVANNI\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Paola\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:17:\"ANSTEE, Quentin M\";i:1;s:13:\"VALENTI, Luca\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:81:\"Update on Treatment Strategies in Patients with Non-Alcoholic Fatty Liver Disease\";s:8:\"\u0000*\u0000title\";s:103:\"Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment\";s:8:\"\u0000*\u0000place\";s:7:\"Sharjah\";s:6:\"\u0000*\u0000pub\";s:7:\"Bentham\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"20\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
